Full text
Earnings transcript
Read the complete earnings call transcript.
SYK
Stryker Corporation
$314.01
12.48
(4.14%)
| Exchange: | NYSE |
| Market Cap: | 120.379B |
| Shares Outstanding: | 336M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Kevin A. Lobo | |||||
| Full Time Employees: | 53000 | |||||
| Address: |
| |||||
| Website: | https://www.stryker.com |
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 20,498,000 | 22,595,000 | 25,116,000 |
| Gross Profit | 12,494,000 | 13,980,000 | 16,065,000 |
| EBITDA | 5,057,000 | 4,938,000 | 6,314,000 |
| Operating Income | 4,281,000 | 5,061,000 | 4,889,000 |
| Net Income | 3,165,000 | 2,993,000 | 3,246,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 39,912,000 | 42,971,000 | 47,844,000 |
| Total Liabilities | 21,319,000 | 22,337,000 | 25,424,000 |
| Total Stockholders Equity | 18,593,000 | 20,634,000 | 22,420,000 |
| Total Debt | 13,494,000 | 14,120,000 | 14,859,000 |
| Cash and Cash Equivalents | 2,971,000 | 3,652,000 | 4,011,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,711,000 | 4,242,000 | 5,044,000 |
| Capital Expenditure | -575,000 | -755,000 | -761,000 |
| Free Cash Flow | 3,136,000 | 3,487,000 | 4,283,000 |
| Net Income | 3,165,000 | 2,993,000 | 3,246,000 |
| Net Change in Cash | 1,127,000 | 681,000 | 359,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 37,437,630.979 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 38,384,563.794 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 37,949,666.667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 8,575,684.821 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 8,792,594.843 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 8,692,974.739 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 8,751,565.936 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 9,040,516.781 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 8,907,809.297 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 12,603,840.707 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 12,922,637.331 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 12,776,223.843 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 23.310 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 23.650 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 22.900 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 11 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: SYK demonstrates strong revenue and net income growth as reported in recent income statements, supported by consistent operating cash flow and free cash flow figures from cash flow statements. This reflects operational efficiency and financial stability, positioning the company well within the medical devices industry.
- Market Leadership in Medical Technology: As highlighted in the company profile, SYK operates in the healthcare sector with a focus on innovative medical and surgical equipment. This aligns with industry trends toward advanced healthcare solutions, providing a competitive edge over peers, as evidenced by strong gross profit margins in key metrics.
- Global Revenue Diversification: Revenue geo segments data indicates a balanced distribution of revenue across multiple regions, reducing dependency on any single market and enhancing resilience against regional economic downturns.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates SYK intrinsic value between $133.06 – $246.02 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about SYK valuation
Is Stryker Corporation (SYK) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Stryker Corporation (SYK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SYK a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SYK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SYK’s P/E ratio?
You can see SYK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SYK?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SYK a good long-term investment?
Whether SYK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SYK
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
4.14
Trading Metrics:
| Open: | 303.26 | Previous Close: | 301.53 | |
| Day Low: | 302.5 | Day High: | 315.12 | |
| Year Low: | 281 | Year High: | 404.87 | |
| Price Avg 50: | 316.58 | Price Avg 200: | 353.98 | |
| Volume: | 2.701M | Average Volume: | 2.513M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeSYK full analysis
Welcome to MARKETSNAP’s SWOT analysis for Stryker Corporation, a heavyweight in the medical technology space. If you’re a long-term investor looking to build wealth through smart picks, you’re in the right place. Today, we’re diving deep into Stryker—known by its ticker SYK—unpacking what makes this company tick, where it shines, where it struggles, and what could shape its future. Let’s get into it with a quick overview, some recent updates, and then a full breakdown of strengths, weaknesses, opportunities, and…
